Immunogenicity of anti-SARS-CoV-2 Comirnaty vaccine in patients with lymphomas and myeloma who underwent autologous stem cell transplantation
Bone Marrow Transplant
.
2022 Jan;57(1):137-139.
doi: 10.1038/s41409-021-01487-4.
Epub 2021 Oct 11.
Authors
Marco Salvini
1
,
Fabrizio Maggi
1
2
,
Camilla Damonte
2
,
Lorenzo Mortara
3
,
Antonino Bruno
4
,
Barbara Mora
1
2
,
Marco Brociner
1
,
Roberta Mattarucchi
1
,
Alessia Ingrassia
1
,
Davide Sirocchi
1
,
Benedetta Bianchi
1
,
Stefania Agnoli
1
,
Matteo Gallazzi
3
4
,
Michele Merli
1
,
Andrea Ferrario
1
,
Raffaella Bombelli
3
,
Daniela Barraco
1
,
Andreina Baj
2
,
Lorenza Bertù
1
,
Paolo A Grossi
1
2
,
Francesco Passamonti
5
6
Affiliations
1
ASST Sette Laghi, Ospedale di Circolo, Varese, Italy.
2
Department of Medicine and Surgery, University of Insubria, Varese, Italy.
3
Laboratory of Immunology and General Pathology, Department of Biotechnology and Life Sciences, University of Insubria, Varese, Italy.
4
Laboratory of Innate Immunity, Unit of Molecular Pathology, Biochemistry, and Immunology, IRCCS MultiMedica, Milan, Italy.
5
ASST Sette Laghi, Ospedale di Circolo, Varese, Italy. francesco.passamonti@uninsubria.it.
6
Department of Medicine and Surgery, University of Insubria, Varese, Italy. francesco.passamonti@uninsubria.it.
PMID:
34635796
PMCID:
PMC8504426
DOI:
10.1038/s41409-021-01487-4
No abstract available
Publication types
Letter
MeSH terms
COVID-19 Vaccines
COVID-19*
Hematopoietic Stem Cell Transplantation*
Humans
Lymphoma*
Multiple Myeloma* / therapy
SARS-CoV-2
Transplantation, Autologous
Substances
COVID-19 Vaccines